Finepart publicerade den 23 november 2023 bolagets delårsrapport för det tredje kvartalet år 2023.
Redeye summarises and comments on Circio’s R&D Webinar on 29 September.
NOSIUM har publicerat bolagets delårsrapport för det tredje kvartalet 2023.
AcuCort har publicerat bolagets delårsrapport för det tredje kvartalet år 2023.
Redeye comments on Ngenic’s Q3 report, where Ngenic reported impressive net sales, which completely ...
iZafe erhåller nya rekordavtal som bekräftar Analysguidens prognoser om en offensiv tillväxtresa.
Akzo Nobel Selektope product on Korean market in 6-12 months Adds Akzo Nobel to list of named custom...
Redeye comments on MGI’s Q3 2023 report, showing stronger sales and underlying profitability than ex...
With stable sales in H1’23/24, Qlucore has continued on the revised, more concentrated path announce...
The recent Medicare price of USD 322 is the latest progress during a quarter of improved commercial ...
Redeye is encouraged to learn that Alzinova’s lead candidate, ALZ-101, met the primary endpoint of s...
Tangiamo publicerade den 29 november 2023 bolagets delårsrapport för det tredje kvartalet 2023 och v...
Redeye comments on the outcome of the TO 2B announcement published today.
Redeye provides a note in relation to NeoDynamics’ Q3 2023 report and its current financial situatio...
NetApp reported strong numbers with share +12%... .
Redeye endorses today's SEK3.6m order for Nanologica's new non-silica based purification media NLAB ...
Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharma com...
Redeye comments on the new AI-designed precision vaccines for hematological malignancies.
Redeye provides an initial take on Harm Reduction Group’s Q3 report, where sales and EBITDA declined...
Signs evaluation agreement with "large global pharma company" To evaluate PharmaShell in depot formu...
